Clinical Trial Update: Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluating the efficacy, safety, and pharmacokinetics of LFG316 in patients with Paroxysmal Nocturnal Hemoglobinuria has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• LFG316

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED | Results posted: 2024-11-01